JP2004502638A5 - - Google Patents

Download PDF

Info

Publication number
JP2004502638A5
JP2004502638A5 JP2001547043A JP2001547043A JP2004502638A5 JP 2004502638 A5 JP2004502638 A5 JP 2004502638A5 JP 2001547043 A JP2001547043 A JP 2001547043A JP 2001547043 A JP2001547043 A JP 2001547043A JP 2004502638 A5 JP2004502638 A5 JP 2004502638A5
Authority
JP
Japan
Prior art keywords
group
hydrogen
alkyl
oxa
hydroxyalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001547043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502638A (ja
Filing date
Publication date
Priority claimed from US09/469,985 external-priority patent/US6358939B1/en
Application filed filed Critical
Publication of JP2004502638A publication Critical patent/JP2004502638A/ja
Publication of JP2004502638A5 publication Critical patent/JP2004502638A5/ja
Withdrawn legal-status Critical Current

Links

JP2001547043A 1999-12-21 2000-12-21 炎症性腸疾患の予防および治療のための生物学的活性ビタミンd化合物の使用 Withdrawn JP2004502638A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/469,985 US6358939B1 (en) 1999-12-21 1999-12-21 Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
PCT/US2000/034913 WO2001046132A1 (en) 1999-12-21 2000-12-21 Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2004502638A JP2004502638A (ja) 2004-01-29
JP2004502638A5 true JP2004502638A5 (enExample) 2008-01-31

Family

ID=23865828

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001547043A Withdrawn JP2004502638A (ja) 1999-12-21 2000-12-21 炎症性腸疾患の予防および治療のための生物学的活性ビタミンd化合物の使用

Country Status (9)

Country Link
US (2) US6358939B1 (enExample)
EP (1) EP1240136A4 (enExample)
JP (1) JP2004502638A (enExample)
KR (1) KR100660508B1 (enExample)
AU (1) AU781113B2 (enExample)
CA (1) CA2395200A1 (enExample)
MX (1) MXPA02006257A (enExample)
NO (1) NO326517B1 (enExample)
WO (1) WO2001046132A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
WO2001042205A2 (en) * 1999-12-02 2001-06-14 The Penn State Research Foundation Treatment of inflammatory bowel disease with vitamin d compounds
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
EP2071332A1 (en) * 2000-11-14 2009-06-17 Techlab, Inc. Method for monitoring persons with IBD using total endogeneous lactoferrin as a marker
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP1587906A2 (en) * 2003-01-10 2005-10-26 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
GB0513984D0 (en) * 2005-07-07 2005-08-17 Teva Pharma Dosage form
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
EP2139462B1 (en) * 2007-03-30 2014-01-22 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
JP2010524973A (ja) * 2007-04-18 2010-07-22 ジョンズ ホプキンス ユニバーシティ カルシトリオールの低カルシウム血性、高抗増殖性類似体
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
AU2010208323B2 (en) 2009-01-27 2016-03-10 Berg Llc Vitamin D3 and analogs thereof for alleviating side effects associated with chemotherapy
EP2464357B1 (en) 2009-08-14 2019-05-22 Berg LLC Vitamin d3 and analogs thereof for treating alopecia
ES2524127T3 (es) 2009-11-20 2014-12-04 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
CA2792278C (en) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
US20130064859A1 (en) * 2011-01-28 2013-03-14 Sarkis K. Mazmanian Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
HUE025567T2 (en) * 2011-08-19 2016-02-29 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Agents containing vasoconstrictors for combination therapy
CA2909941A1 (en) 2013-04-24 2014-10-30 Salk Institute For Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
SG10201709894RA (en) 2013-05-29 2018-01-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
BR112015030518A2 (pt) 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
KR102343093B1 (ko) 2015-02-23 2021-12-24 삼성전자주식회사 식기 세척기 및 그 제어방법
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化psa組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312806A (en) 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US4638043A (en) 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5824313A (en) 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
JP2811353B2 (ja) 1990-07-06 1998-10-15 ゼリア新薬工業株式会社 炎症性腸疾患予防・治療剤
ZA916555B (en) 1990-08-27 1993-04-28 Lilly Co Eli Method of treating inflammatory bowel disease
US5391555A (en) 1991-11-12 1995-02-21 Miles Inc. Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
DE4221961A1 (de) * 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
US5294630A (en) 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
GB9223061D0 (en) 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
DE59409873D1 (de) 1993-04-20 2001-10-25 Hexal Ag Wirkstoffpflaster
GB9309422D0 (en) 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
GB9314400D0 (en) 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
GB9315253D0 (en) 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
DE4405545A1 (de) * 1994-02-22 1995-08-31 Dietl Hans Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
ES2130522T3 (es) 1994-12-14 1999-07-01 Duphar Int Res Compuestos de vitamina d y metodo para preparar estos compuestos.
WO1996022973A1 (fr) 1995-01-23 1996-08-01 Chugai Seiyaku Kabushiki Kaisha Derives de vitamine d3 de 2-substitution
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
US5569680A (en) 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
DK0836506T4 (da) 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE69606680T2 (de) 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
AU710931B2 (en) 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
GB9607034D0 (en) 1996-04-03 1996-06-05 Leo Pharm Prod Ltd Chemical compounds
US5834016A (en) 1996-04-04 1998-11-10 Cilag Ag Liposome-based topical vitamin D formulation
US5891865A (en) 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
DE69834109T2 (de) * 1997-05-16 2007-04-19 Woman & Infants Hospital 3-epi-vitamin d2 verbindungen und ihre anwendungen
NL1006072C2 (nl) 1997-05-16 1998-11-17 Jacobs Johannes J Vergister voor het onder aërobe omstandigheden vergisten van dierlijke mest, inrichting en werkwijze voor het onder aërobe omstandigheden vergisten van dierlijke mest onder toepassing van een dergelijke vergister.
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
EP0927721A1 (de) * 1997-12-17 1999-07-07 Schering Aktiengesellschaft Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US6214373B1 (en) * 1999-10-07 2001-04-10 Snowden-Sutton Associates, Inc. Nutritional composition for treating inflammatory bowel diseases
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
WO2001042205A2 (en) * 1999-12-02 2001-06-14 The Penn State Research Foundation Treatment of inflammatory bowel disease with vitamin d compounds
MXPA03001969A (es) * 2000-09-08 2003-06-24 Wisconsin Alumni Res Found 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.

Similar Documents

Publication Publication Date Title
US6426340B1 (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-FUDCA)
JP2005526833A5 (enExample)
ATE359069T1 (de) Therapeutische zusammenstellungen
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
JP2005530743A5 (enExample)
JPH10503522A (ja) 化学療法剤とともに使用するための防御性プロスタグランジン
JP2007524627A5 (enExample)
JPH0692847A (ja) 骨粗鬆症治療剤
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
JP2002544227A5 (enExample)
JP2003520208A5 (enExample)
CA2483002A1 (en) New pharmaceutical composition
US7214671B2 (en) Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
JP2023520405A5 (enExample)
KR100450293B1 (ko) 만성장염의치료에유용한알카노일l-카르니틴의용도
EP0567352B1 (en) Use of 1-alpha,24(R)-dihydroxy-22(E)-dehydro-vitamin D3 for the manufacture of a medicament for the treatment of osteoporosis
JP4510445B2 (ja) 筋肉欠乏症を処置するのに意図した医薬を製造するためにイチョウ抽出物の使用
NORDENRAM et al. A histopathologic study of replanted teeth with superficially demineralized root surfaces in Java monkeys
JP2025031720A5 (enExample)
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
JP2005512956A6 (ja) 筋肉欠乏症を処置するのに意図した医薬を製造するためにイチョウ抽出物の使用
Mintz Autologous Transfusion Endorsed-Reply
JP2004506605A5 (enExample)
EP1143949B1 (en) 19-nor-vitamin d3 compounds with calcemic activity
JPH0121A (ja) 骨の粗鬆化防止剤